Securities Class Action Filed Against Zoetis Over Companion‑Animal Sales Claims

Overview

• Plaintiff firms have announced a securities class action covering purchases from January 14, 2025 through May 6, 2026 and set a July 27, 2026 deadline to move for lead‑plaintiff status.
• The complaint alleges Zoetis made false or misleading statements about market share, veterinarian adoption, and accelerating sales for Librela, Simparica Trio, Apoquel and Cytopoint.
• Plaintiffs say Librela prescription growth weakened after FDA safety warnings about neurological risks, Simparica Trio lost share to a lower‑priced rival, and Apoquel/Cytopoint ceded ground to a newly launched competing treatment.
• Multiple law firms (including Rosen Law, DJS Law Group and the Schall Law Firm) are soliciting investors to join the case or seek lead‑plaintiff roles and note no class has yet been certified.
• The suit asserts claims under Sections 10(b) and 20(a) and Rule 10b‑5 but remains at an early procedural stage so the allegations are unproven and any financial impact on Zoetis will depend on how the litigation and related disclosures proceed.